ClinicalTrials.gg
Not yet recruitingNCT07943455Updated Nov 17, 2026

Addressing Violence in the Context of Opioid Use Disorder Care

An Early Phase 1 interventional study of SHE-OUD in Sexual Violence, Opioid Use Disorder and Posttraumatic Stress Disorder, sponsored by Lifespan. Not yet recruiting. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Lifespan · Early Phase 1, Interventional, and Screening

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Study summary

The goal of this clinical trial is to learn if the SHE-OUD program helps women who are receiving buprenorphine treatment for opioid use disorder (OUD), have experienced sexual violence, and have PTSD. The study will examine whether the program is practical to deliver, safe, and acceptable to participants. The main questions it aims to answer are: Is SHE-OUD feasible, acceptable, and satisfying for women in OUD treatment who have experienced sexual violence and have PTSD? Does SHE-OUD increase participants' engagement in mental health treatment for PTSD? The study will first evaluate SHE-OUD in a small open trial, then compare SHE-OUD to a control condition in a randomized trial to see if SHE-OUD increases engagement in mental health treatment. Participants will: complete the SHE-OUD program (or, in the randomized trial, either SHE-OUD or the control condition), continue regular buprenorphine treatment for OUD, complete assessments at the start of the study and at a 1-month follow-up, and answer questions about mental health, treatment engagement, and satisfaction with the program.

Read the detailed description

The goal of this R61/R33 is to adapt SHE for use in outpatient OUD treatment (SHE-OUD), and evaluate its feasibility, acceptability, and outcomes among women with SV and PTSD in MOUD treatment. To be included, women must report current OUD, be enrolled in OUD treatment, be treated with buprenorphine, report prior SV, report current PTSD, and not be engaged in mental health treatment for PTSD. As SHE was developed for women veterans, only women are included in this phase of development/testing. Activities in the R61 Phase focus on building, adapting, and testing the feasibility of SHE-OUD. Following the assessment, decision, adaptation, production, topical experts integration, training, testing (ADAPT-ITT) framework, information from informant interviews (N = 10), focus groups (N = 30), stakeholder interviews (N = 6) and a Research Advisory Board will be leveraged to adapt the program. Next, the intervention will be evaluated in an open trial (N = 20) of SHE-OUD among women meeting study eligibility criteria to demonstrate the feasibility (Aim 1a) and safety (Aim 1b) of the research design, feasibility, acceptability, satisfaction and utility of SHE-OUD (i.e., completion rate, acceptance, satisfaction, and utility scores; Aim 2a,2b,2c,2d). Assessments will explore shifts in mental treatment engagement outcomes at a 1-month follow-up (Aim 3). To proceed to the R33, 80% of participants will complete the 1-month follow-up within 2 weeks of the due date (Aim 1a), and no serious study-related adverse events will be reported (Aim 1b). Further, 80% will complete the assigned SHE-OUD modules (Aim 2a), participants must report: an average acceptability score of >3 (out of 5) for each SHE-OUD component (Aim 2b); an average >24 on the Client-Satisfaction Questionnaire-8 (Aim 2c); and an average >90 on the Utility and Impact Questionnaires (Aim 2d). Regarding mental health treatment engagement, assessments will examine whether outcomes are trending in the correct direction at follow-up (Aim 3).

02

Conditions studied

  • Sexual Violence
  • Opioid Use Disorder
  • Posttraumatic Stress Disorder

Keywords

  • sexual violence
  • opioid use disorder
  • posttraumatic stress disorder
03

In context

Opioid-Related Disorders

1,473 studies on the registry are indexed under Opioid-Related Disorders; 290 are open to participants now.

This study's planned enrollment of 20 is below the median of 63 across 1,167 interventional studies indexed under Opioid-Related Disorders.

Browse Opioid-Related Disorders studies →

Lead sponsor

Lifespan is the lead sponsor of 27 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years and above at enrollment
  • Female
  • Current Opioid Use Disorder (OUD will be determined by the treating physician at each study site using DSM-5 criteria)
  • Actively engaged in medication treatment for opioid use disorder (MOUD) with Buprenorphine or Methadone
  • Screen positive for lifetime sexual victimization (SV)
  • Screen positive for current PTSD

Exclusion criteria

Exclusion criteria:

  • Engaged in current mental health treatment for PTSD (i.e., has received at least one session of evidence- based PTSD treatment in the past 4 weeks);
  • Non-English speaking. Measures will be administered in English.
  • Current symptoms of psychosis
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Early Phase 1
Primary purpose
Screening
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    SHE-OUD

    Screening Intervention

    Behavioral: SHE-OUD

Interventions

  • BehavioralSHE-OUD

    The SHE-OUD intervention provides screening for sexual victimization and PTSD among individuals seeking MOUD treatment with the goal of enhancing mental health treatment utilization, and enhancing OUD treatment outcomes. Aftereffects of sexual victimization are addressed (i.e., intimate partner violence, substance use) if participants endorse a risk for these concerns. All participants are provided with brief intervention for sexual victimization, PTSD, and the intersection of sexual victimization and OUD.

06

What researchers measure

Primary outcomes

  1. Mental Health Treatment Initiation

    Number of participants who engage in mental health treatment for PTSD and general mental health concern, assessed by the Treatment Services Review (self-report). Treatment initiation is defined as reporting at least one service appointment in the past 30 days. This is a binary variable (yes/no), with the positive outcome being "yes" (treatment initiated).

    Time frame: Measured at baseline and 1 month follow-up.

  2. Mental Health Treatment Utilization

    Number of mental health treatment sessions attended, assessed by the Treatment Services Review (self-report). Treatment utilization is defined as reporting at having two or more services. This is a binary variable (yes/no), with the positive outcome being "yes" (treatment utilized).

    Time frame: Measured at baseline and 1 month follow-up.

Secondary outcomes

  1. PTSD Symptoms

    Change From Baseline in The Primary Care PTSD Screen for DSM-5 scores at 1 month. Scores range from 0 to 5, with higher scores indicating greater PTSD symptoms.

    Time frame: Assessed at baseline and 1-month follow-up

  2. Intimate Partner Violence

    Change From Baseline in HITS score at 1 month. Scores range from 4 to 20, with higher scores indicating greater intimate partner violence risk.

    Time frame: Assessed at baseline and 1-month follow-up.

  3. Polysubstance Use

    Change From Baseline in Timeline Follow Back scores at 1 month. Frequency and type of substance use in the past 30 days will be assessed. Scores range from 0-30, with a cumulative count of substance use days or heavy drinking days.

    Time frame: Assessed at baseline and 1-month follow-up.

  4. Opioid Use

    Change From Baseline in Timeline Follow Back scores at 1 month. Frequency of non-prescription opioid use in the past 30 days will be assessed. Scores range from 0-30, with a cumulative count of days engaging in opioid use.

    Time frame: Assessed at baseline and 1-month follow-up.

  5. Non-fatal overdose

    Change From Baseline in Timeline Follow Back scores at 1 month. Frequency of non-fatal overdoses in the past 30 days will be assessed. Scores range from 0-30, with a cumulative count of days in which non-fatal overdoses occurred.

    Time frame: Assessed at baseline and 1-month follow-up.

  6. OUD Medication Adherence

    Change From Baseline in Timeline Follow Back scores at 1 month. Self-reported data on daily buprenorphine and methadone medication adherence in the past 30 days will be assessed. Scores range from 0-30, with a cumulative count of days adhering to OUD medication.

    Time frame: Assessed at baseline and 1-month follow-up.

  7. OUD Treatment Retention

    Change From Baseline in Timeline Follow Back scores at 1 month. Self-reported data on number of missed appointments and treatment dropout will be assessed. Scores range from 0-30, with a cumulative count of days in which a participant missed an appointment or dropped out of treatment.

    Time frame: Assessed at baseline and 1-month follow-up.

  8. Revictimization

    Change From Baseline in 2-item Life Events Checklist at 1 month. A positive score indicates revictimization. This is a binary variable (yes/no), with the positive outcome being "yes" (revicitimization)

    Time frame: Assessed at baseline and 1-month follow-up.

  9. Trauma-related shame

    Change From Baseline in Trauma-Related Shame Inventory (Short Form) scores at 1 month. Scores range from 0-30, with higher scores indicating more severe levels of trauma-related shame.

    Time frame: Assessed at baseline and 1 month follow up.

  10. Self-blame

    Change From Baseline in Rape Attribution scores at 1 month. Scores range from 5 to 25, with higher scores indicating greater self blame across subscales (behavioral self-blame, characterological self-blame, blaming the rapist, blaming society, and blaming chance).

    Time frame: Assessed at baseline and 1 month follow up.

  11. Pain

    Change From Baseline in PROMIS® Numeric Rating Scale v.1.0 - Pain Intensity scores at 1 month. Scores range from 0 to 10, with higher scores indicating more severe pain.

    Time frame: Assessed at baseline and 1 month follow up.

  12. Depression

    Change From Baseline in Patient Health Questionnaire (PHQ-9) scores at 1 month. Scores range from 0 to 27, with higher scores indicating greater depression severity.

    Time frame: Assessed at baseline and 1 month follow up.

  13. Anxiety

    Change From Baseline in Generalized Anxiety Disorder-7 (GAD-7) scores at 1 month. Scores range from 0 to 21, with higher scores indicating greater anxiety.

    Time frame: Assessed at baseline and 1 month follow up.

  14. Motivation for change

    Change From Baseline in Readiness to Change (RCTQ) scores for each change target (PTSD, IPV, and polysubstance use) at 1 month. Scores range from -8 to +8 for each subscale, with higher scores indicating greater readiness to change.

    Time frame: Assessed at baseline, post-intervention, and 1 month follow up.

  15. Attitudes towards Psychological Care

    Change from Attitudes Toward Seeking Professional Psychological Help Scale-Short Version (ATSPPH-SF) at 1 month. Scores range from 10 to 40, with higher scores indicating a more positive attitude toward seeking professional psychological help.

    Time frame: Assessed at baseline and 1 month follow up.

  16. Stigma

    Change from Self-Stigma of Seeking Help and the Stigma Scale for Receiving Psychological Help at 1 month. Scores for the Self-Stigma of Seeking Help range from 10 to 50, with higher scores indicating a greater perceived threat to one's self-worth associated with seeking help. Scores of the Stigma Scale for Receiving Psychological Help range from 0-15, with higher scores indicating greater public stigma.

    Time frame: Assessed at baseline and 1 month follow up.

  17. Outcomes expectancies

    Change from the Disclosure Expectation Scale at 1 month. Scores for Disclosure Expectations Scale range from 10 to 50; Higher scores on the positive expectations subscale indicates more positive disclosure expectations, while higher scores on the negative expectations subscale indicates more negative disclosure expectations.

    Time frame: Assessed at baseline and 1 month follow up.

  18. Intentions to seek treatment

    Change from the adapted Intentions to Seek Counseling Inventory at 1 month. Scores for the Intentions to Seek Counseling Inventory range from 11-44, with higher scores reflecting a greater general willingness to seek help.

    Time frame: Assessed at baseline and 1 month follow up.

  19. Self-efficacy

    Change from Self-Efficacy to Seek Mental Health Care at 1 month. Scores from the Self-Efficacy to Seek Mental Health Care range from 9-90, with higher scores reflecting greater self efficacy (perceived behavioral control).

    Time frame: Assessed at baseline and 1 month follow up.

  20. Contextual Factors

    Change from Life Circumstances Scale at 1 month. Higher scores across each subscale (i.e., transportation, scheduling, cost, access) indicate greater impact on care.

    Time frame: Assessed at baseline and 1 month follow up.

Other outcomes

  1. Intervention Satisfaction

    Client Satisfaction Questionnaire (CSQ) will assess overall satisfaction with the intervention. Scores range from 8 to 32, with higher scores indicating greater satisfaction.

    Time frame: Assessed immediately post-intervention as a descriptive measure (no comparison group).

  2. Intervention Acceptability

    Acceptability of Intervention (AIM) Measure will assess intervention acceptability. Scores range from 4 to 20, with higher scores indicating higher acceptability.

    Time frame: Assessed immediately post-intervention as a descriptive measure (no comparison group).

  3. Intervention Utility

    The adapted Utility Questionnaire (UQ) will assess perceived intervention utility. Scores range from 0 to 56, with higher scores indicating higher utility.

    Time frame: Assessed immediately post-intervention as a descriptive measure (no comparison group).

  4. Intervention Impact

    The adapted Impact Questionnaire (IQ) will assess intervention impact. Scores range from 0 to 28, with higher scores indicating higher impact.

    Time frame: Assessed immediately post-intervention as a descriptive measure (no comparison group).

  5. Intervention Usability

    The CIAS satisfaction measure (Ondersma et al., 2005) will be used to assess system usability. Scores range from 7 to 35, with higher scores indicating higher usability.

    Time frame: Assessed immediately post-intervention as a descriptive measure (no comparison group).

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — De-identified data and protocol information will be shared in accordance with the data sharing and management plan.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: Data and study information will be made available as soon as it is available at the completion of the study.

Access criteria: Data sharing agreements will be established for access to data. Data can also be accessed through the public repository.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Aug 2027, 8 months later.

Of 54 non-industry phase 1 interventional studies under Opioid-Related Disorders, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 47. This study's planned 8 months is below that.

Counting every sponsor, half of 78 studies reached it within 19 months; a quarter within 9 and three quarters within 33.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2026
First posted
Nov 17, 2026
StartEst.
Dec 5, 2026
Primary completionEst.
Aug 15, 2027
CompletionEst.
Aug 15, 2027
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07943455
Lead sponsor
Lifespan
Responsible party
Lindsay Orchowski Ph.D. (Professor, Rhode Island Hospital) — Principal investigator
First posted
Nov 17, 2026
Start date
Dec 5, 2026 (estimated)
Primary completion
Aug 15, 2027 (estimated)
Completion
Aug 15, 2027 (estimated)
Last update
Nov 17, 2026

Study contacts

Lindsay Orchowski, PhD
Contact
lindsay_orchowski@brown.edu
412-559-2936
Prachi Bhuptani, PhD
Contact
prachi_bhuptani@brown.edu

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion